Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Est. Listeners
Based on iTunes & Spotify (publisher stats).
- Per-Episode Audience
Est. listeners per new episode within ~30 days
1 - 1,000 - Monthly Reach
Unique listeners across all episodes (30 days)
1 - 5,000 - Active Followers
Loyal subscribers who consistently listen
1 - 500
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
Success Lessons from a Serial Entrepreneur
May 14, 2025
Unknown duration
He’s setting the world of Inflammation and Immunology research on fire!
Apr 16, 2025
Unknown duration
Patient Advocacy is NOT optional!
Mar 19, 2025
Unknown duration
Taming the Behemoth of Adverse Drug Reactions with Zach Brooks
Feb 12, 2025
Unknown duration
A cup of Kombucha that ignited the war on sugar addiction
Jan 15, 2025
Unknown duration
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 5/14/25 | Success Lessons from a Serial Entrepreneur | Enjoy this podcast with Leonard Mazur, the co-founder, Chairman, and CEO of Citius Pharmaceuticals, a late-stage biopharma company focused on developing critical care. With over 50 years in the industry, there are many success lessons to be learned as Leonard has co-founded several companies, including Akrimax Pharmaceuticals and Genesis Pharmaceuticals, which he successfully sold to Pierre Fabre in 2003. DisclaimerThe information contained in this website and podcast arepurely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may beconstrued as a recommendation or endorsement of any of the companies discussed.Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur. | — | ||||||
| 4/16/25 | He’s setting the world of Inflammation and Immunology research on fire! | Today we are honored to have Dr. Josep Bassaganya-Riera, President and CEO of NImmune Biopharma, to talk about how his company is leveraging computational modeling and bioinformatics to develop new therapeutics.DisclaimerThe information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur. | — | ||||||
| 3/19/25 | Patient Advocacy is NOT optional! | In this podcast, we are pleased to have Mike Walsh, CEO of Patient Advocacy Strategies as our guest. Patient advocacy may seem like a “nice to have” or an afterthought. In this podcast you’ll learn why the opposite is true – that it’s important to glean input from patient groups early on in the lifecycle and throughout the course of developing solutions for patients. Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur. | — | ||||||
| 2/12/25 | Taming the Behemoth of Adverse Drug Reactions with Zach Brooks | It’s shocking that 106,000 people die every year from adverse drug reactions. Moreover, 350,000 people are hospitalized every year, 1.3 million people go to the ER, and it is the fourth leading cause of death in the United States. Adverse drug reactions are a behemoth problem, costing the economy almost half trillion dollars.DisclaimerThe information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur. | — | ||||||
| 1/15/25 | A cup of Kombucha that ignited the war on sugar addiction | In this episode, filed at Science Square in Atlanta, we speak with David Francis and Mighten Yip of Palate Therapeutics, whose mission is to alter people’s food preferences away from sugary foods using therapeutic mouthwash. Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur. | — | ||||||
| 12/18/24 | Shooting for the Stars with Astrocyte Pharmaceuticals | With over 1.5 million people suffering traumatic brain injuries a year, 80,000 stroke victims, and millions of concussions, the impact that brain impairment has on society is not to be ignored. We spoke with William Korinek of Astrocyte Pharmaceuticals, who is developing neuroprotein therapies for these conditions. Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur. | — | ||||||
| 11/20/24 | Knee-deep in meniscus redesign: the story of Atlanta’s OrthoPreserve | There are 1.4 million meniscus procedures performed in the US and Europe every single year. Most of those are meniscetomy which is when the meniscus is removed. The problem is that once it is gone, so is the cushioning that protects the knee joint and cartilage, accelerating arthritis. A quarter of people continue to have pain after a few years. Millions of people have this procedure and it’s not the best answer. Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur. | — | ||||||
| 10/16/24 | Confronting the task of delivering scalable amounts of protein to a billion cows | Our guest today is Dr. Ivan Liachko, the CEO of Seattle-based Phase Genomics, a company whose core technology is ultra-long range genome sequencing. He’s also the founder of Genome Startup Day, dedicated to helping new biotech entrepreneurs transition from academic settings into industry and entrepreneurship. Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur. | — | ||||||
| 8/14/24 | What Pharma really thinks about Startups | Tune in for this insightful podcast with David Weinstock, the Vice President of Discovery Oncology at Merck, to find out what pharma investors really think when they are interviewing startups looking for funding. Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur. | — | ||||||
| 7/10/24 | Meet the Reluctant Founder who is waging war on Antibiotic Resistant Infections! | Our guest today is another Atlanta luminary, Dr. Marvin Whiteley, the founder and CSO of SynthBiome, Inc. Deaths are expected to increase over the next 20-30 years due to antibiotic resistant infections. It’s common for people to go into the hospital for something innocuous, get an infection, and find that the bacterium doesn’t respond to antibiotic. There are strains infecting people outside of clinical settings, as well. As there are millions of deaths caused by this each year, the alarm bells are starting to go off because we are not developing a lot of new antibiotics. How can this trend be stopped? Disclaimers The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur. | — | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 6/12/24 | How this founder raised $230MM in capital | Carter Cliff is the CEO of Papillon Therapeutics. Papillon is advancing genetic medicines for life threatening conditions including Cystinosis, Friedreich's ataxia, Danon disease, and Alzheimer's disease, and the company is currently partnered with Novartis on a phase 1/2 trial for their lead candidate in cystinosis. Carter has a multi-decade career in biotech and life sciences and is also a venture partner at Saisei Ventures where he helps launch biotechnology companies, and has raised over $200MM in funding across various ventures. Enjoy the show! Disclaimers The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur. | — | ||||||
| 5/15/24 | Targeting the Ribosome: taking on platinum resistance in solid ovarian tumors in a safer way! | Today we’ve got Dr. Jonathan Arambula and Dr. Krystle Karoscik of InnovoTex, an oncology therapeutics company developing a platform of smart molecules capable of circumventing drug resistance often seen in treating ovarian cancer. They’re doing it in a safer way – hear about all this and more by listening to the show! Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur. | — | ||||||
| 4/17/24 | Price controls for medicine – a chilling effect for innovators? | We’re going to talk with Peter Pitts, President of Center for Medicine in the Public Interest, about the IRA, which is impacting every company in biotech. The Inflation Reduction Act, or IRA, authorizes the price negotiation for a group of medicines selected by the government and, interestingly, allows no public pronouncements after the fact, by the companies. Disclaimers The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur. | — | ||||||
| 3/20/24 | How to get funding for your Biotech: what investors look for | Today we’re excited to have Subh Roy who will share his insights about how to get funding for your biotech. Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur. | — | ||||||
| 2/14/24 | Finding a cure for the neglected diseases of the world’s poor: an interview with drug discovery superstar Dr. Dennis Liotta | Dr. Dennis Liotta is very humble but don’t let that fool you – underneath the poised demeanor he’s a impassioned drug discovery giant who has made a significant contribution to improving the disease state of the world’s poor. The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur. | — | ||||||
| 1/17/24 | Atlanta life sciences companies in OVERDRIVE: don’t sleep on ‘em! | Today we have four very special guests, some friends of mine, who are going to share with us the story behind all the momentum driving life sciences in Atlanta. · Eddie Lai represents the MetroAtlanta Chamber of Commerce · Courtney Law represents a group called Biolocity, which bridges Emory and Georgia Tech · Ryan Lawler is from Biosparks Labs, funded by Georgia Technology Ventures, supporting the life science community in Atlanta · Suna Lumeh is from a venture capital firm called Portal Innovations This was a great group so I hope you’ll listen to the show! Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur. | — | ||||||
| 12/13/23 | Making vaccine delivery as simple as the flick of a lighter | Our guest today is Gaurav Byagathvalli, a Geoge Tech alum and the CEO of Piezo Therapeurtics, a company developing an innovative nucleic acid delivery platform for DNA and mRNA vaccines. Instead of using complicated equipment they use simplified circuits, analogous to what is in a lighter, to product the same impulse. They then use microneedles, which function as electrodes, to conduct those pulses into your skin resulting in highly targeted, localized delivery. Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur. | — | ||||||
| 11/8/23 | Conquering the Disease State with Nolan Townsend | Our guest today is Nolan Townsend, the CEO of LEXEO Therapeutics, which focused on expanding the application of crisper gene therapies past rare diseases where they’ve generally been applied to more prevalent kinds of diseases. What got me excited for the talk was the enthusiasm that Nolan expressed for the application of genetic therapies to more common diseases, which is where all the costs live. This could have a very broad impact on society’s healthcare systems. Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur. | — | ||||||
| 10/11/23 | The problem with how people take their medications | Today I am really excited to have Charles Gellman, CEO of HiDO Health. HiDO is a company that is focused on using artificial intelligence to help patients manage their medications for chronic disease. Each year, almost 250,000 in America die as a result of medical errors associated with lack of adherence to a prescription schedule, making it the third largest cause of death in the US. Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur. | — | ||||||
| 9/13/23 | Pills are not the only solution to big pain! With Dr. Amy Baxter | Our guest today is Dr. Amy Baxter, the CEO of Pain Care Labs, a company dedicated to using mechanical platforms such as vibrating devices to alleviate fear and pain associated with needles as well as reducing muscular skeletal pain in adults. Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur. | — | ||||||
| 8/16/23 | Mastering the Single Use Scope: the story of Xenocor | Today we are joined by Charles DeCoster, CEO, and Tony Watson, COO, of Xenocor, a company that is revolutionizing laparoscopic surgery with a new scope they call Saberscope. This device was designed to be less expensive, more effective at providing the surgeon with available light, and safer for the patient. Laparoscopic surgery was invented in the 1980’s and the technology platform is now 30 years old. It has not changed dramatically since then. The single use model eliminates a lot of the frustrations. You open up the package, you plug it in. That’s the whole workflow. A reusable scope’s workflow, from the time it gets opened in the OR to the time it gets back to the OR to be used again, is quite onerous. By making it single use, they are reducing waste and simplifying the process. Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur. | — | ||||||
| 7/12/23 | 2023 Update: Our past guests - where are they now? | This episode we’re doing something different. We’re visiting some of the most compelling stories and CEOs of our earlier editions, to update their journeys. I wanted to do this for two reasons. · The people in this industry are some of the grittiest, most determined, and most philanthropic, in terms of their commitment to their science and patients, people that I have ever known. · By following these individual journeys I hope somehow to demonstrate the incredibly fast pace of innovations taking place. Our guests are: · Abdulkader Rahmo, PhD · Torrey Smith · Dr. Nikhil Shah · Tan Rasab · Jacob Glanville Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur. | — | ||||||
| 6/14/23 | From Jurassic Park to the cutting edge of mRNA innovation: the story of Dr. Pooja Tiwari | Recently on the Biotech and Life Science CEO’s podcast, we’ve been talking about the speed at which change is occurring in the life sciences. And nowhere is that clearer than in the field of mRNA. By now everyone must know that the COVID vaccines were created literally days after the genome of the virus had been sequenced. But I don’t think we’ve still processed what that really means. Our guest today is Dr. Pooja Tiwari, the founder of Arnav Biotech, dedicated to the design and manufacture of both custom and cataloged mRNA for use in therapeutic vaccine, diagnostic, and even agricultural applications. Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur. | — | ||||||
| 5/10/23 | Quirky Civil War Medicine Stories to make you chuckle! | In this podcast, we are joined by historian Dr. Nicolas Hoffmann who recounts a slew of quirky Civil War medicine stories that will have you rolling in laughter. Let’s go! Over the last few months of this podcast, we’ve had the opportunity to learn about tiny pill-sized endoscopes that can be swallowed and controlled on their path through the digestive tract by the healthcare provider. We’ve heard about the prospects for a universal flu vaccine whose chemistry would be consistent from one year to the next whose efficacy could be better than 90%. A smaller, less expensive tool for targeted genetic sequencing. And many other amazing innovations. In other words, things are happening really fast. But today, our thought is a little bit different. We’re going to try to juxtapose history with what is currently happening in an effort to demonstrate exactly what those changes are and how fast those changes are going to be. Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur. | — | ||||||
| 4/12/23 | Capturing endoscopic surgical procedures on “TV” is now a thing! | Today we are going to discuss advancements in improving the efficiency of those clinical trials. Our guest is Ian Strug who is the co-founder and Chief Revenue Officer at Virgo Surgical Video Solutions. Virgo provides cloud video capture, management, and artificial intelligence analysis for endoscopic medicine. Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur. | — | ||||||
Showing 25 of 36
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
3 placements across 3 markets.
Chart Positions
3 placements across 3 markets.